{"id":5053,"date":"2013-05-18T15:45:17","date_gmt":"2013-05-18T15:45:17","guid":{"rendered":"https:\/\/medicalcriteria.com\/web\/aecg\/"},"modified":"2025-05-13T20:27:58","modified_gmt":"2025-05-13T20:27:58","slug":"aecg","status":"publish","type":"post","link":"https:\/\/medicalcriteria.com\/web\/es\/aecg\/","title":{"rendered":"Indicaciones para Electrocardiograf\u00eda Ambulatoria (ECGA)"},"content":{"rendered":"<div class=\"7ca9444b8380138fe077da07353677a4\" data-index=\"1\" style=\"float: none; margin:0px 0 0px 0; text-align:center;\">\n<script async src=\"https:\/\/pagead2.googlesyndication.com\/pagead\/js\/adsbygoogle.js\"><\/script>\r\n<!-- MC 2019- Horizontal -->\r\n<ins class=\"adsbygoogle\"\r\n     style=\"display:block\"\r\n     data-ad-client=\"ca-pub-0127150553352455\"\r\n     data-ad-slot=\"3806776041\"\r\n     data-ad-format=\"auto\"\r\n     data-full-width-responsive=\"true\"><\/ins>\r\n<script>\r\n     (adsbygoogle = window.adsbygoogle || []).push({});\r\n<\/script>\n<\/div>\n<p><span id=\"result_box\" lang=\"es\"><span title=\"Improvements in solid-state digital technology have enhanced transtelephonic transmission of electrocardiography (ECG) data and increased the accuracy of software-based analysis systems.\">Hay muchas posibles aplicaciones cl\u00ednicas del ECG de 12 derivaciones. El ECG puede reflejar los cambios asociados a procesos primarios o secundarios de miocardio (por ejemplo, los asociados con enfermedad de arterias coronarias, hipertensi\u00f3n, cardiomiopat\u00eda, o trastornos infiltrativos), anormalidades metab\u00f3licas y de electrolitos, y los efectos terap\u00e9uticos o t\u00f3xicos de f\u00e1rmacos o dispositivos. La electrocardiograf\u00eda sirve como el est\u00e1ndar de oro para el diagn\u00f3stico no invasivo de arritmias y trastornos de la conducci\u00f3n, y ocasionalmente es el \u00fanico marcador de la presencia de enfermedades card\u00edacas.<\/span><\/span><span id=\"result_box\" lang=\"es\"><\/span><br \/>\n<!--more--><br \/>\n<span title=\"The recommendations are classified according to the system used by the ACC and AHA.\">Las recomendaciones se clasifican seg\u00fan el sistema utilizado por la ACC y la AHA.\u00a0<\/span><span title=\"The classification system is as follows:\">El sistema de clasificaci\u00f3n es la siguiente:<br \/>\n<\/span><\/p>\n<ul>\n<li><span id=\"result_box\" lang=\"es\"><span title=\"Class I\u2014Conditions for which there is evidence and\/or general agreement that a given procedure or treatment is useful and effective.\">Clase I: Condiciones para las que existe evidencia y\/o acuerdo general de que un procedimiento o tratamiento es \u00fatil y eficaz.<\/span><\/span><\/li>\n<li><span id=\"result_box\" lang=\"es\"><span title=\"Class II\u2014Conditions for which there is conflicting evidence and\/or a divergence of opinion about the usefulness\/efficacy of a procedure or treatment.\">Clase II: Condiciones para las cuales hay evidencia conflictiva y\/o divergencia de opini\u00f3n acerca de la utilidad\/eficacia de un procedimiento o tratamiento.\u00a0<\/span><span title=\"Class IIa\u2014The weight of evidence\/opinion is in favor of usefulness\/efficacy.\">Clase IIa: el peso de la evidencia\/opini\u00f3n est\u00e1 a favor de la utilidad\/eficacia.\u00a0<\/span><span title=\"Class IIb\u2014The usefulness\/efficacy is less well established by evidence\/opinion.\">Clase IIb: La utilidad\/eficacia est\u00e1 menos establecida por la evidencia\/opini\u00f3n.<\/span><\/span><\/li>\n<li><span id=\"result_box\" lang=\"es\"><span title=\"Class III\u2014Conditions for which there is evidence and\/or general agreement that the procedure\/treatment is not useful\/effective, and in some cases may be harmful.\">Clase III: Condiciones para las cuales hay evidencia y\/o acuerdo general de que el procedimiento\/tratamiento no es \u00fatil\/efectivo y en algunos casos puede ser perjudicial.<\/span><\/span><\/li>\n<\/ul>\n<p><span id=\"result_box\" lang=\"es\"><span title=\"Class III\u2014Conditions for which there is evidence and\/or general agreement that the procedure\/treatment is not useful\/effective, and in some cases may be harmful.\"><br \/>\n<\/span><strong><span title=\"Indications for AECG to Assess Symptoms Possibly Related to Rhythm Disturbances\">Indicaciones para\u00a0<\/span><\/strong><\/span><span id=\"result_box\" lang=\"es\"><span title=\"Indications for AECG to Assess Symptoms Possibly Related to Rhythm Disturbances\"><strong>ECGA para Evaluar los S\u00edntomas Posiblemente Relacionados con Alteraciones del Ritmo<\/strong><br \/>\n<\/span><span title=\"Class I\"><br \/>\nClase I<br \/>\n<\/span><\/span><\/p>\n<ol>\n<li><span id=\"result_box\" lang=\"es\"><span title=\"Patients with unexplained syncope, near syncope, or episodic dizziness in whom the cause is not obvious\">Pacientes con s\u00edncope inexplicado, pre s\u00edncope o v\u00e9rtigo epis\u00f3dico en los que la causa no es evidente<\/span><\/span><\/li>\n<li><span id=\"result_box\" lang=\"es\"><span title=\"Patients with unexplained recurrent palpitation\">Pacientes con palpitaciones recurrentes inexplicadas<\/span><\/span><\/li>\n<\/ol>\n<p><span id=\"result_box\" lang=\"es\"><span title=\"Class IIb\">Clase IIb<br \/>\n<\/span><\/span><\/p>\n<ol>\n<li><span id=\"result_box\" lang=\"es\"><span title=\"Patients with episodic shortness of breath, chest pain, or fatigue that is not otherwise explained\">Pacientes con episodios de disnea, dolor de pecho o fatiga que no se explica de otro modo<\/span><\/span><\/li>\n<li><span id=\"result_box\" lang=\"es\"><span title=\"Patients with neurological events when transient atrial fibrillation or flutter is suspected\">Pacientes con eventos neurol\u00f3gicos cuando se sospecha de fibrilaci\u00f3n o aleteo auricular transitorio<\/span><\/span><\/li>\n<li><span id=\"result_box\" lang=\"es\"><span title=\"Patients with symptoms such as syncope, near syncope, episodic dizziness, or palpitation in whom a probable cause other than an arrhythmia has been identified but in whom symptoms persist despite treatment of this other cause\">Pacientes con s\u00edntomas como s\u00edncope, pre s\u00edncope, v\u00e9rtigo epis\u00f3dico, o palpitaciones en el que la causa probable no sea una arritmia ya identificada, pero que los s\u00edntomas persistan a pesar del tratamiento de esta otra causa<\/span><\/span><\/li>\n<\/ol>\n<p><span id=\"result_box\" lang=\"es\"><span title=\"Class III\">Clase III<br \/>\n<\/span><\/span><\/p>\n<ol>\n<li><span id=\"result_box\" lang=\"es\"><span title=\"Patients with symptoms such as syncope, near syncope, episodic dizziness, or palpitation in whom other causes have been identified by history, physical examination, or laboratory tests\">Pacientes con s\u00edntomas como s\u00edncope, pre s\u00edncope, v\u00e9rtigo epis\u00f3dico, o palpitaciones en el que otras causas han sido identificadas por historia, exploraci\u00f3n f\u00edsica o pruebas de laboratorio<\/span><\/span><\/li>\n<li><span id=\"result_box\" lang=\"es\"><span title=\"Patients with cerebrovascular accidents, without other evidence of arrhythmia\">Pacientes con accidentes cerebrovasculares, sin otra evidencia de arritmia<\/span><\/span><\/li>\n<\/ol>\n<p><span id=\"result_box\" lang=\"es\"><span title=\"Patients with cerebrovascular accidents, without other evidence of arrhythmia\"><br \/>\n<\/span><strong><span title=\"Indications for AECG Arrhythmia Detection to Assess Risk for Future Cardiac Events in Patients Without Symptoms From Arrhythmia\">Indicaciones para<\/span><\/strong><\/span><strong><span id=\"result_box\" lang=\"es\"><span title=\"Indications for AECG Arrhythmia Detection to Assess Risk for Future Cardiac Events in Patients Without Symptoms From Arrhythmia\">\u00a0Detecci\u00f3n<\/span><\/span><span id=\"result_box\" lang=\"es\"><span title=\"Indications for AECG Arrhythmia Detection to Assess Risk for Future Cardiac Events in Patients Without Symptoms From Arrhythmia\">\u00a0Arritmias por\u00a0<\/span><\/span><\/strong><span id=\"result_box\" lang=\"es\"><span title=\"Indications for AECG Arrhythmia Detection to Assess Risk for Future Cardiac Events in Patients Without Symptoms From Arrhythmia\"><strong>ECGA para Evaluar el Riesgo de Futuros Eventos Card\u00edacos en Pacientes sin S\u00edntomas por Arritmias<\/strong><br \/>\n<\/span><\/span><\/p>\n<p><span id=\"result_box\" lang=\"es\"><span title=\"Class I\">Clase I<br \/>\n<\/span><\/span><\/p>\n<p style=\"padding-left: 40px;\"><span id=\"result_box\" lang=\"es\"><span title=\"None\">Ninguno<br \/>\n<\/span><\/span><\/p>\n<p><span id=\"result_box\" lang=\"es\"><span title=\"Class IIb\">Clase IIb<br \/>\n<\/span><\/span><\/p>\n<ol>\n<li><span id=\"result_box\" lang=\"es\"><span title=\"Post-MI patients with LV dysfunction (ejection fraction &lt;\/=40%)\">Pacientes post-IAM con disfunci\u00f3n ventricular izquierda (fracci\u00f3n de eyecci\u00f3n &lt;\/= 40%)<\/span><\/span><\/li>\n<li><span id=\"result_box\" lang=\"es\"><span title=\"Patients with CHF\">Pacientes con ICC<\/span><\/span><\/li>\n<li><span id=\"result_box\" lang=\"es\"><span title=\"Patients with idiopathic hypertrophic cardiomyopathy\">Pacientes con miocardiopat\u00eda hipertr\u00f3fica idiop\u00e1tica<\/span><\/span><\/li>\n<\/ol>\n<p><span id=\"result_box\" lang=\"es\"><span title=\"Class III\">Clase III<br \/>\n<\/span><\/span><\/p>\n<ol>\n<li><span id=\"result_box\" lang=\"es\"><span title=\"Patients who have sustained myocardial contusion\">Pacientes que han sufrido una contusi\u00f3n mioc\u00e1rdica<\/span><\/span><\/li>\n<li><span id=\"result_box\" lang=\"es\"><span title=\"Systemic hypertensive patients with LV hypertrophy\">Pacientes con hipertensi\u00f3n arterial\u00a0<\/span><\/span><span id=\"result_box\" lang=\"es\"><span title=\"Systemic hypertensive patients with LV hypertrophy\">sist\u00e9mica\u00a0<\/span><\/span><span id=\"result_box\" lang=\"es\"><span title=\"Systemic hypertensive patients with LV hypertrophy\">con hipertrofia ventricular izquierda<br \/>\n<\/span><\/span><\/li>\n<li><span id=\"result_box\" lang=\"es\"><span title=\"Post-MI patients with normal LV function\">Pacientes post-IAM con la funci\u00f3n normal ventricular izquierda<br \/>\n<\/span><\/span><\/li>\n<li><span id=\"result_box\" lang=\"es\"><span title=\"Preoperative arrhythmia evaluation of patients for noncardiac surgery\">Evaluaci\u00f3n de arritmias preoperatoria de pacientes para cirug\u00eda no cardiaca<\/span><\/span><\/li>\n<li><span id=\"result_box\" lang=\"es\"><span title=\"Patients with sleep apnea\">Pacientes con apnea del sue\u00f1o<\/span><\/span><\/li>\n<li><span id=\"result_box\" lang=\"es\"><span title=\"Patients with valvular heart disease\">Pacientes con enfermedad card\u00edaca valvular<\/span><\/span><\/li>\n<\/ol>\n<p><span id=\"result_box\" lang=\"es\"><span title=\"Patients with valvular heart disease\"><br \/>\n<\/span><span title=\"Indications for Measurement of HRV to Assess Risk for Future Cardiac Events in Patients Without Symptoms From Arrhythmia\"><strong>Indicaciones para la Medici\u00f3n de la\u00a0<\/strong><\/span><\/span><strong><span id=\"result_box\" class=\"short_text\" lang=\"es\"><span class=\"hps\">Variabilidad de la Frecuencia<\/span>\u00a0<span class=\"hps\">Cardiaca (VFC<\/span>)<\/span><\/strong><span id=\"result_box\" lang=\"es\"><span title=\"Indications for Measurement of HRV to Assess Risk for Future Cardiac Events in Patients Without Symptoms From Arrhythmia\"><strong>\u00a0para E<\/strong><\/span><\/span><span id=\"result_box\" lang=\"es\"><span title=\"Indications for Measurement of HRV to Assess Risk for Future Cardiac Events in Patients Without Symptoms From Arrhythmia\"><strong>valuar el Riesgo de Futuros Eventos Card\u00edacos en Pacientes sin S\u00edntomas por Arritmias<\/strong><br \/>\n<\/span><span title=\"Class I\"><br \/>\nClase I<br \/>\n<\/span><\/span><\/p>\n<p style=\"padding-left: 40px;\"><span id=\"result_box\" lang=\"es\"><span title=\"None\">Ninguno<br \/>\n<\/span><\/span><\/p>\n<p><span id=\"result_box\" lang=\"es\"><span title=\"Class IIb\">Clase IIb<br \/>\n<\/span><\/span><\/p>\n<ol>\n<li><span id=\"result_box\" lang=\"es\"><span title=\"Post-MI patients with LV dysfunction\">Pacientes post-IAM con disfunci\u00f3n del VI<\/span><\/span><\/li>\n<li><span id=\"result_box\" lang=\"es\"><span title=\"Patients with CHF\">Pacientes con ICC<\/span><\/span><\/li>\n<li><span id=\"result_box\" lang=\"es\"><span title=\"Patients with idiopathic hypertrophic cardiomyopathy\">Pacientes con miocardiopat\u00eda hipertr\u00f3fica idiop\u00e1tica<\/span><\/span><\/li>\n<\/ol>\n<p><span id=\"result_box\" lang=\"es\"><span title=\"Patients with idiopathic hypertrophic cardiomyopathy\"><br \/>\n<\/span><span title=\"Class III\">Clase III<br \/>\n<\/span><\/span><\/p>\n<ol>\n<li><span id=\"result_box\" lang=\"es\"><span title=\"Post-MI patients with normal LV function\">Pacientes post-IAM con la funci\u00f3n normal del VI<\/span><\/span><\/li>\n<li><span id=\"result_box\" lang=\"es\"><span title=\"Diabetic subjects to evaluate for diabetic neuropathy\">Pacientes diab\u00e9ticos para evaluar la neuropat\u00eda diab\u00e9tica<\/span><\/span><\/li>\n<li><span id=\"result_box\" lang=\"es\"><span title=\"Patients with rhythm disturbances that preclude HRV analysis (ie, atrial fibrillation)\">Pacientes con alteraciones del ritmo que impiden el an\u00e1lisis de la variabilidad de la FC (es decir, la fibrilaci\u00f3n auricular)<\/span><\/span><\/li>\n<\/ol>\n<p><span id=\"result_box\" lang=\"es\"><span title=\"Patients with rhythm disturbances that preclude HRV analysis (ie, atrial fibrillation)\"><br \/>\n<\/span><span title=\"Indications for AECG to Assess Antiarrhythmic Therapy\"><strong>Indicaciones para ECGA para Evaluar el Tratamiento Antiarr\u00edtmico<\/strong><br \/>\n<\/span><span title=\"Class I\"><br \/>\nClase I<br \/>\n<\/span><\/span><\/p>\n<ol>\n<li><span id=\"result_box\" lang=\"es\"><span title=\"To assess antiarrhythmic drug response in individuals in whom baseline frequency of arrhythmia has been characterized as reproducible and of sufficient frequency to permit analysis\">Para evaluar la respuesta al f\u00e1rmaco antiarr\u00edtmico en individuos en los que la frecuencia basal de la arritmia se ha caracterizado como reproducible y de frecuencia suficiente para permitir el an\u00e1lisis<\/span><\/span><\/li>\n<\/ol>\n<p><span id=\"result_box\" lang=\"es\"><span title=\"Class IIa\">Clase IIa<br \/>\n<\/span><\/span><\/p>\n<ol>\n<li><span id=\"result_box\" lang=\"es\"><span title=\"To detect proarrhythmic responses to antiarrhythmic therapy in patients at high risk\">Para detectar respuestas pro arr\u00edtmicas del tratamiento antiarr\u00edtmico en pacientes con alto riesgo<\/span><\/span><\/li>\n<\/ol>\n<p><span id=\"result_box\" lang=\"es\"><span title=\"Class IIb\">Clase IIb<br \/>\n<\/span><\/span><\/p>\n<ol>\n<li><span id=\"result_box\" lang=\"es\"><span title=\"To assess rate control during atrial fibrillation\">Para evaluar el control de la frecuencia durante la fibrilaci\u00f3n auricular<\/span><\/span><\/li>\n<li><span id=\"result_box\" lang=\"es\"><span title=\"To document recurrent or asymptomatic nonsustained arrhythmias during therapy in the outpatient setting\">Para documentar arritmias no sostenidas recurrentes o asintom\u00e1ticas durante el tratamiento de forma ambulatoria<\/span><\/span><\/li>\n<\/ol>\n<p><span id=\"result_box\" lang=\"es\"><span title=\"Class III\">Clase III<br \/>\n<\/span><\/span><\/p>\n<p style=\"padding-left: 40px;\"><span id=\"result_box\" lang=\"es\"><span title=\"None\">Ninguno<br \/>\n<\/span><\/span><\/p>\n<p><span id=\"result_box\" lang=\"es\"><span title=\"Indications for AECG to Assess Pacemaker and ICD Function\"><strong>Indicaciones para ECGA para Evaluar la Funci\u00f3n de Marcapasos y Cardio-Desfibrilador Implantable (CDI)<\/strong><br \/>\n<\/span><span title=\"Class I\"><br \/>\nClase I<br \/>\n<\/span><\/span><\/p>\n<ol>\n<li><span id=\"result_box\" lang=\"es\"><span title=\"Evaluation of frequent symptoms of palpitation, syncope, or near syncope to assess device function to exclude myopotential inhibition and pacemakermediated tachycardia and to assist in the programming of enhanced features such as rate responsivity and automatic mode switching\">Evaluaci\u00f3n de s\u00edntomas frecuentes de palpitaciones, s\u00edncope, o pre-s\u00edncope para evaluar la funci\u00f3n del dispositivo y excluir la inhibici\u00f3n miopotenciales y taquicardia secundaria al marcapasos, y para ayudar en la programaci\u00f3n de caracter\u00edsticas mejoradas tales como la capacidad de respuesta y la tasa de cambio a modo autom\u00e1tico<\/span><\/span><\/li>\n<li><span id=\"result_box\" lang=\"es\"><span title=\"Evaluation of suspected component failure or malfunction when device interrogation is not definitive in establishing a diagnosis\">Evaluaci\u00f3n de fallo de un componente sospechoso o mal funcionamiento cuando la interrogaci\u00f3n del dispositivo no es definitiva en el establecimiento de un diagn\u00f3stico<\/span><\/span><\/li>\n<li><span id=\"result_box\" lang=\"es\"><span title=\"To assess the response to adjunctive pharmacological therapy in patients receiving frequent ICD therapy\">Para evaluar la respuesta al tratamiento farmacol\u00f3gico coadyuvante en pacientes que reciben terapia CDI frecuentes<\/span><\/span><\/li>\n<\/ol>\n<p><span id=\"result_box\" lang=\"es\"><span title=\"Class IIb\">Clase IIb<br \/>\n<\/span><\/span><\/p>\n<ol>\n<li><span id=\"result_box\" lang=\"es\"><span title=\"Evaluation of immediate postoperative pacemaker function after pacemaker or ICD implantation as an alternative or adjunct to continuous telemetric monitoring\">Evaluaci\u00f3n de la funci\u00f3n de marcapasos postoperatorio inmediato despu\u00e9s de la implantaci\u00f3n del marcapasos o CDI como una alternativa o complemento a la monitorizaci\u00f3n telem\u00e9trica continua<\/span><\/span><\/li>\n<li><span id=\"result_box\" lang=\"es\"><span title=\"Evaluation of the rate of supraventricular arrhythmias in patients with implanted defibrillators\">Evaluaci\u00f3n de la tasa de arritmias supra ventriculares en pacientes con desfibriladores implantados<\/span><\/span><\/li>\n<\/ol>\n<p><span id=\"result_box\" lang=\"es\"><span title=\"Class III\">Clase III<br \/>\n<\/span><\/span><\/p>\n<ol>\n<li><span id=\"result_box\" lang=\"es\"><span title=\"Assessment of ICD\/pacemaker malfunction when device interrogation, ECG, or other available data (chest radiograph and so forth) are sufficient to establish an underlying cause\/diagnosis\">Evaluaci\u00f3n de\u00a0<\/span><\/span><span id=\"result_box\" lang=\"es\"><span title=\"Assessment of ICD\/pacemaker malfunction when device interrogation, ECG, or other available data (chest radiograph and so forth) are sufficient to establish an underlying cause\/diagnosis\">mal funcionamiento\u00a0<\/span><\/span><span id=\"result_box\" lang=\"es\"><span title=\"Assessment of ICD\/pacemaker malfunction when device interrogation, ECG, or other available data (chest radiograph and so forth) are sufficient to establish an underlying cause\/diagnosis\">CDI\/<\/span><\/span><span id=\"result_box\" lang=\"es\"><span title=\"Assessment of ICD\/pacemaker malfunction when device interrogation, ECG, or other available data (chest radiograph and so forth) are sufficient to establish an underlying cause\/diagnosis\">marcapasos<\/span><\/span><span id=\"result_box\" lang=\"es\"><span title=\"Assessment of ICD\/pacemaker malfunction when device interrogation, ECG, or other available data (chest radiograph and so forth) are sufficient to establish an underlying cause\/diagnosis\"> cuando la interrogaci\u00f3n del dispositivo, ECG, u otros datos disponibles (radiograf\u00eda de t\u00f3rax, etc.) son suficientes para establecer una causa\/diagn\u00f3stico subyacente<\/span><\/span><\/li>\n<li><span id=\"result_box\" lang=\"es\"><span title=\"Routine follow-up in asymptomatic patients\">Para el seguimiento, en pacientes asintom\u00e1ticos<\/span><\/span><\/li>\n<\/ol>\n<p><span id=\"result_box\" lang=\"es\"><span title=\"Routine follow-up in asymptomatic patients\"><br \/>\n<\/span><span title=\"Indications for AECG for Ischemia Monitoring\"><strong>Indicaciones para ECGA para Monitoreo de Isquemia<\/strong><br \/>\n<\/span><\/span><\/p>\n<p><span id=\"result_box\" lang=\"es\"><span title=\"Class I\">Clase I<br \/>\n<\/span><\/span><\/p>\n<p style=\"padding-left: 40px;\"><span id=\"result_box\" lang=\"es\"><span title=\"None\">Ninguno<br \/>\n<\/span><\/span><\/p>\n<p><span id=\"result_box\" lang=\"es\"><span title=\"Class IIa\">Clase IIa<br \/>\n<\/span><\/span><\/p>\n<ol>\n<li><span id=\"result_box\" lang=\"es\"><span title=\"Patients with suspected variant angina\">Pacientes con sospecha de\u00a0<\/span><\/span><span id=\"result_box\" lang=\"es\"><span title=\"Patients with suspected variant angina\">variante<\/span><\/span><span id=\"result_box\" lang=\"es\"><span title=\"Patients with suspected variant angina\">\u00a0de angina<br \/>\n<\/span><\/span><\/li>\n<\/ol>\n<p><span id=\"result_box\" lang=\"es\"><span title=\"Class IIb\">Clase IIb<br \/>\n<\/span><\/span><\/p>\n<ol>\n<li><span id=\"result_box\" lang=\"es\"><span title=\"Evaluation of patients with chest pain who cannot exercise\">Evaluaci\u00f3n de pacientes con dolor de pecho que no pueden realizar ejercicios<\/span><\/span><\/li>\n<li><span id=\"result_box\" lang=\"es\"><span title=\"Preoperative evaluation for vascular surgery of patients who cannot exercise\">Evaluaci\u00f3n preoperatoria de cirug\u00eda vascular de pacientes que no pueden realizar ejercicios<\/span><\/span><\/li>\n<li><span id=\"result_box\" lang=\"es\"><span title=\"Patients with known CAD and atypical chest pain syndrome\">Pacientes con s\u00edndrome de dolor tor\u00e1cico at\u00edpico y enfermedad de arterias coronarias conocida<\/span><\/span><\/li>\n<\/ol>\n<p><span id=\"result_box\" lang=\"es\"><span title=\"Class III\">Clase III<br \/>\n<\/span><\/span><\/p>\n<ol>\n<li><span id=\"result_box\" lang=\"es\"><span title=\"Initial evaluation of patients with chest pain who are able to exercise\">Evaluaci\u00f3n inicial de los pacientes con dolor tor\u00e1cico que son capaces de realizar ejercicios<\/span><\/span><\/li>\n<li><span id=\"result_box\" lang=\"es\"><span title=\"Routine screening of asymptomatic subjects\">Screening de rutina de sujetos asintom\u00e1ticos<\/span><\/span><\/li>\n<\/ol>\n<p><span id=\"result_box\" lang=\"es\"><span title=\"Routine screening of asymptomatic subjects\"><br \/>\n<\/span><span title=\"Indications for Holter Monitoring (24 - 48 hours)\"><strong>Indicaciones para el monitoreo Holter (24 &#8211; 48 horas)<\/strong><br \/>\n<\/span><span title=\"Traditionally, ambulatory monitoring has been used to determine the cause of palpitations and syncope and, to a lesser degree, to identify ventricular ectopy or nonsustained ventricular tachycardia in patients at potential risk for sudden cardiac death.\">Tradicionalmente, la monitorizaci\u00f3n ambulatoria se ha utilizado para determinar la causa de palpitaciones y s\u00edncope y, en menor grado, para identificar ectopia ventricular o taquicardia ventricular no sostenida en pacientes con riesgo potencial de muerte cardiaca s\u00fabita.\u00a0<\/span><span title=\"Atrial fibrillation (AF) has become an increasingly important indication for ambulatory monitoring, predominantly as a tool to monitor the efficacy and safety of pharmacological and nonpharmacological therapies.\">La fibrilaci\u00f3n auricular (FA) se ha convertido en una indicaci\u00f3n cada vez m\u00e1s importante para la monitorizaci\u00f3n ambulatoria, predominantemente como una herramienta para monitorizar la eficacia y la seguridad de las terapias farmacol\u00f3gicas y no farmacol\u00f3gicas.\u00a0<\/span><span title=\"It is also used to identify asymptomatic AF as a potential source of cryptogenic stroke.\">Tambi\u00e9n se utiliza para identificar la FA asintom\u00e1tica como una fuente potencial de ictus criptog\u00e9nico.<\/span><\/span><\/p>\n<p>&nbsp;<\/p>\n<p><strong>Bibliograf\u00eda:<\/strong><\/p>\n<ol>\n<li>Crawford MH, Bernstein SJ, Deedwania PC, DiMarco JP, Ferrick KJ, Garson A Jr, Green LA, Greene HL, Silka MJ, Stone PH, Tracy CM, Gibbons RJ, Alpert JS, Eagle KA, Gardner TJ, Gregoratos G, Russell RO, Ryan TH, Smith SC Jr. ACC\/AHA Guidelines for Ambulatory Electrocardiography. A report of the American College of Cardiology\/American Heart Association Task Force on Practice Guidelines (Committee to Revise the Guidelines for Ambulatory Electrocardiography). Developed in collaboration with the North American Society for Pacing and Electrophysiology. J Am Coll Cardiol. 1999 Sep;34(3):912-48. <a href=\"https:\/\/pubmed.ncbi.nlm.nih.gov\/10483977\/\" target=\"_blank\" rel=\"noopener noreferrer\">[Medline]<\/a><\/li>\n<li>Zimetbaum P, Goldman A. Ambulatory arrhythmia monitoring: choosing the right device. Circulation. 2010 Oct 19;122(16):1629-36. <a href=\"https:\/\/pubmed.ncbi.nlm.nih.gov\/20956237\/\" target=\"_blank\" rel=\"noopener noreferrer\">[Medline]<\/a><\/li>\n<\/ol>\n<p>&nbsp;<\/p>\n<p>Creado May 18, 2013.<\/p>\n\n<div style=\"font-size: 0px; height: 0px; line-height: 0px; margin: 0; padding: 0; clear: both;\"><\/div>","protected":false},"excerpt":{"rendered":"<p>Hay muchas posibles aplicaciones cl\u00ednicas del ECG de 12 derivaciones. El ECG puede reflejar los cambios asociados a procesos primarios o secundarios de miocardio (por ejemplo, los asociados con enfermedad de arterias coronarias, hipertensi\u00f3n, cardiomiopat\u00eda, o trastornos infiltrativos), anormalidades metab\u00f3licas y de electrolitos, y los efectos terap\u00e9uticos o t\u00f3xicos de f\u00e1rmacos o dispositivos. La electrocardiograf\u00eda [&hellip;]<\/p>\n","protected":false},"author":2,"featured_media":0,"comment_status":"closed","ping_status":"open","sticky":false,"template":"","format":"standard","meta":{"_lmt_disableupdate":"no","_lmt_disable":"no","_exactmetrics_skip_tracking":false,"_exactmetrics_sitenote_active":false,"_exactmetrics_sitenote_note":"","_exactmetrics_sitenote_category":0,"footnotes":""},"categories":[26],"tags":[1975,1350,1349,1976,1977,1978,74,73],"class_list":["post-5053","post","type-post","status-publish","format-standard","hentry","category-cardiology","tag-aecg","tag-ambulatorio","tag-ambulatory","tag-ecg","tag-electrocardiografia","tag-electrocardiography","tag-indicaciones","tag-indications"],"modified_by":"Guillermo Firman","_links":{"self":[{"href":"https:\/\/medicalcriteria.com\/web\/es\/wp-json\/wp\/v2\/posts\/5053","targetHints":{"allow":["GET"]}}],"collection":[{"href":"https:\/\/medicalcriteria.com\/web\/es\/wp-json\/wp\/v2\/posts"}],"about":[{"href":"https:\/\/medicalcriteria.com\/web\/es\/wp-json\/wp\/v2\/types\/post"}],"author":[{"embeddable":true,"href":"https:\/\/medicalcriteria.com\/web\/es\/wp-json\/wp\/v2\/users\/2"}],"replies":[{"embeddable":true,"href":"https:\/\/medicalcriteria.com\/web\/es\/wp-json\/wp\/v2\/comments?post=5053"}],"version-history":[{"count":3,"href":"https:\/\/medicalcriteria.com\/web\/es\/wp-json\/wp\/v2\/posts\/5053\/revisions"}],"predecessor-version":[{"id":9308,"href":"https:\/\/medicalcriteria.com\/web\/es\/wp-json\/wp\/v2\/posts\/5053\/revisions\/9308"}],"wp:attachment":[{"href":"https:\/\/medicalcriteria.com\/web\/es\/wp-json\/wp\/v2\/media?parent=5053"}],"wp:term":[{"taxonomy":"category","embeddable":true,"href":"https:\/\/medicalcriteria.com\/web\/es\/wp-json\/wp\/v2\/categories?post=5053"},{"taxonomy":"post_tag","embeddable":true,"href":"https:\/\/medicalcriteria.com\/web\/es\/wp-json\/wp\/v2\/tags?post=5053"}],"curies":[{"name":"wp","href":"https:\/\/api.w.org\/{rel}","templated":true}]}}